ABSTRACT
OBJECTIVE: To evaluate the influence of CYP2C19 genetic polymorphism on omeprazole pharmacokinetics. METHODS: Cochrane library, PubMed, Embase and CNKI databases were searched for trials investigating the influence of CYP2C19 genetic polymorphism on omeprazole pharmacokinetics reported before February 2012.Meta-analysis was performed by RevMan 5.1 software. RESULTS: Twelve retrospective studies, eight in English and four in Chinese, were included. Meta-analysis showed that CYP2C19 polymorphism significantly influenced the ρmax, AUC, t1/2 and CL/F. The ρmax, AUC, t1/2 and CL/F in PM genotype group were higher than those in HEM group, and those in HEM group were significantly higher than in EM group. And the CL/F in EM group was significantly higher than that in HEM group followed by that in PM group. CONCLUSION: CYP2C19 genetic polymorphism affects omeprazole exposure significantly, but there are still other influencing factors. Large prospective studies are needed.